Navigation Links
ArunA Biomedical Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security

ATHENS, Ga., March 31 /PRNewswire/ -- ArunA Biomedical, Inc., a leader in human embryonic stem cell derived products, announced today that it has been awarded a Department of Defense contract to develop an environmental biosensor utilizing its human stem cell technology.


The company will further develop a human embryonic stem cell derived cellular model for use in a prototype biosensor developed by the Naval Research Laboratory and previously studied by the University of Georgia. Current cell sources have a limited lifespan in the field requiring frequent replacement thereby reducing the efficiency and accuracy of testing environmental toxins. ArunA is well positioned to enhance the Naval Research Laboratory's work in this area by offering a robust consistent population of human cells and expanding the capability of sensor technology.

"Effective monitoring and regulation of environmental contamination remains a major challenge of great importance for both military and civilian populations," commented David Ray, ArunA CEO. "ArunA is pleased to have an opportunity to further develop a technology that could aide national security and field combat."

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. For more information, visit:

This press release contains forward-looking statements regarding the company's potential impact on scientific research and collaborations with third parties. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward-looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.

SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Announces Co-development of Fully Validated Induced Pluripotent Stem Cell Kit
2. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
3. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
4. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
7. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing
8. Collexis Connects Biomedical Researchers and Clinical Scientists with the Collexis Expert Platform for Translational Research
9. The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program
10. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
11. Environmental Tectonics Corporations BioMedical Divisions Hyperbaric Chambers Address U.S. President Obamas Initiative to Computerize Medical Records
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
Breaking Biology Technology:
(Date:6/22/2016)... -- On Monday, the Department of Homeland Security (DHS) ... for the Biometric Exit Program. The Request for Information ... explains that CBP intends to add biometrics to confirm ... States , in order to deter visa overstays, ... Logo - ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
Breaking Biology News(10 mins):